BioCryst Pharmaceuticals, Inc.

US$7.69As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:BCRXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 6.61%
Div yield —
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.51
PE TTM —
TSR TTM 5.05%
Mkt cap US$1.979B
ROIC 125.97%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$8.78
14.23%
(76.90%)
Hold 2|8|7|12|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.08
0.09
0.09
0.09
1.96%
13.11%
6.29%
5.91%
Revenue$M
169.1
170.0
177.9
176.6
8.78%
10.80%
13.35%
8.59%
Peers (US$1.979B)
Cap (US$)
PE
2.037B
13.23x
Capital
TTM
5Y
10Y
Leveragex
1.512
(2.243)
(1.366)
EBIT/Intx
0.928
0.105
0.126
Own earn%
260.28
(2.91)
(18.68)
Sh yield%
10.52
42.67
41.78
Owners
Insiders/Inst%
12.24
29.46
Short interest%
4.09
SBC / revenue%
2.69
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
5–11
$1 testx
0.2
Incr. ROIC%
13